Johnson & Johnson Stock

$152.28

0.06% yesterday

NYSE, Jun 25, 10:10 pm CET

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Johnson & Johnson Stock price

$152.28

+12.61 9.03% 5Y

NYSE, Closing price Wed, Jun 25 2025

+0.09 0.06%

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$366.4b

Enterprise Value

$379.9b

Net debt

$13.5b

Cash

$38.8b

Shares outstanding

2.4b

Valuation (TTM | estimate)

P/E

16.94 | 13.91

P/S

4.10 | 4.01

EV/Sales

4.25 | 4.16

EV/FCF

18.65

P/B

4.69

Dividends

DPS

$4.91

Yield 1Y | 5Y

3.22% | 2.78%

Growth 1Y | 5Y

4.47% | 5.54%

Payout 1Y | 3Y

84.80% | 53.58%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$89.3b | $91.3b

EBITDA

$30.7b | $34.3b

EBIT

$23.4b

Net Income

$21.8b | $26.3b

Free Cash Flow

$20.4b

Growth (TTM | estimate)

Revenue

4.30% | 2.79%

EBITDA

-3.18% | 11.18%

EBIT

-3.64%

Net Income

-43.32% | 87.19%

Free Cash Flow

8.91%

Margin (TTM | estimate)

Gross

68.34%

EBITDA

34.33% | 37.56%

EBIT

26.16%

Net

24.41% | 28.84%

Free Cash Flow

22.80%

EPS

$8.99

FCF per Share

$8.47

Short interest

0.80%

Employees

138.10k

Rev per Employee

$640.00k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

25 Analysts have issued a Johnson & Johnson forecast:

11x Buy

44%

14x Hold

56%

More details on Analyst Estimates Including Price Targets

25 Analysts have issued a Johnson & Johnson forecast:

Buy

44%

Hold

56%

Analyst Estimates with Stock Price Targets

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	89,331 89,331	4% 4% 100%
- Direct Costs	28,281 28,281	9% 9% 32%
Gross Profit	61,050 61,050	2% 2% 68%
- Selling and Administrative Expenses	22,724 22,724	4% 4% 25%
- Research and Development Expense	16,915 16,915	11% 11% 19%
EBITDA	30,668 30,668	3% 3% 34%
- Depreciation and Amortization	7,296 7,296	2% 2% 8%
EBIT (Operating Income) EBIT	23,372 23,372	4% 4% 26%
Net Profit	21,810 21,810	43% 43% 24%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Johnson & Johnson Stock News

Positive

Seeking Alpha

●

2 days ago

Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential

Johnson & Johnson is a stable, dividend-growth powerhouse with 62 years of increases and a 3.44% forward yield, ideal for conservative, long-term investors. Despite recent legal headwinds and flat core growth, JNJ remains undervalued, trading at a significant discount to the sector median P/E. Talc litigation overhang has depressed sentiment, but 95% of cases are resolved and market recovery su...

Positive

Seeking Alpha

●

2 days ago

How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years

The Dividend Income Accelerator Portfolio balances income, growth, and capital appreciation, now enhanced by the global diversification from Allianz and LVMH. We focus on financially healthy companies with sustainable dividends and strong competitive advantages, optimizing risk-reward through sector and geographic diversification. The portfolio's Weighted Average Dividend Yield [FWD] of 4.05% a...

Positive

Seeking Alpha

●

2 days ago

Best Dividend Kings: June 2025

Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a collective 2025 growth rate of 5.19%, despite some downward earnings revisions. Seventeen Dividend Kings appear undervalued and offer long-term annualized expected returns of at least 10%, based on ...

More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office	United States
CEO	Joaquin Duato
Employees	138,100
Founded	1887
Website	www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now